AstraZeneca reports Phase III data

AstraZeneca (AZN; LSE:AZN) reported data from three Phase III trials showing that its Crestor rosuvastatin HMG-CoA reductase

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE